Regenerative Medicine Center Opens at Southwest College of Naturopathic Medicine and Health Sciences

The Neil Riordan Center for Regenerative Medicine Focuses on Non-Opioid Treatments of Pain

(Tempe, Arizona, October 2, 2018)–Southwest College of Naturopathic Medicine & Health Sciences team will cut the ribbon for the opening of the new Neil Riordan Center for Regenerative Medicine on November 15 at 4:00 p.m. This affiliation between SCNM and Neil H. Riordan, PA, PhD, a research leader in stem cell therapy, will accelerate the development of this safe and innovative option for the treatment of acute and chronic pain. The Neil Riordan Center for Regenerative Medicine is staffed by an interdisciplinary team of physicians, and housed in SCNM’s LEED Platinum certified Community Commons.

Regenerative medicine, particularly autologous stem cell therapy, utilizes a patient’s own stem cells to promote healing, reduce inflammation and stimulate tissue repair. People with acute and chronic pain, including elite athletes, may benefit from the growth factors, natural anti-inflammatory activity, and regenerative properties of autologous stem cell therapy.

Over 100 million Americans suffer from chronic pain at an annual cost estimated at exceeding $620 billion, the many of whom are currently treated using opioids. This has led to wide-spread abuse and addiction to prescription opioids and illicit drugs including heroin. Opioid addiction and abuse has been attributed to 37,000 deaths each year nationally and 1,763 deaths of Arizonans from opioid overdoses in the past fifteen months. Stem cell therapy promises to limit the reliance on opioids thereby decreasing the potential for opioid addiction and abuse.

Neil Riordan, PA, PhD, is a pioneer in the field of applied stem cell research. In addition to collaboration with major universities in the United States, research and patient care is currently being conducted at Dr. Riordan’s other laboratories and clinics in Dallas, Texas and Panama City, Panama. He is an author on more than seventy peer-reviewed research publications, including clinical studies that explore stem cell therapy’s potential in treating conditions such as autism, multiple sclerosis, and rheumatoid arthritis.

Dr. Riordan is the author of two books on stem cell therapy: Stem Cell Therapy: A Rising Tide – How Stem Cells are Disrupting Medicine and Changing Lives and MSC (Mesenchymal Stem Cells): Clinical Evidence Leading Medicine’s Next Frontier.

We welcome any questions or comments. Please contact Kirsten Texler at k.texler@scnm.edu for more information.

Image of Southwest College of Naturopathic Medicine Logo and Tag Line

A leader in inspiring, teaching and providing multiple modalities in the scope of naturopathic medicine, Southwest College of Naturopathic Medicine not only educates but also elevates society’s awareness of the power of holistic medicine. Campus highlights include a fully accredited four-year naturopathic doctoral program, a robust medical clinic open to the public, a dedicated pain relief and regenerative medicine center, innovative and inspirational public events, an on-site medicinary and multiple opportunities for ground-breaking research. Additionally, the SCNM Sage Foundation highlights the focus on philanthropy instilled in students and faculty as they provide care for underserved communities in seven satellite locations. Southwest College of Naturopathic Medicine is dedicated to the idea that every person deserves high-quality fully integrated healthcare and creates an impact on the world through providing a private non-profit education in the culturally rich state of Arizona.

Acclaimed Guitarist Sonny Mayo on Stem Cell Therapy in Panama

From:  The EXPLODING HUMAN with Bob Nickman

Image of Sonny Mayo

SONNY MAYO, former guitarist for bands like Ugly Kid Joe and Snot, talks to me about getting STEM CELL THERAPY in Panama for a genetic heart condition. After two heart attacks and unpleasant side-effects from heart medications, Sonny was introduced to stem cell therapy through listening to a Joe Rogan podcast.  Raising money through GoFundMe, he was able too make the trip and receive treatment which is not yet legal in the United States.  Sonny is a stellar example of taking back his health treatment from an often limited and close-minded medical  system.  This is an important message as heart disease is the #1 killer in our country!

Original Link: http://theexplodinghuman.libsyn.com/episode-23-sonny-mayo-stem-cell-healing

For more information about stem cell therapy for heart disease, please visit: https://www.cellmedicine.com/stem-cell-therapy-for-heart-failure/

Stem Cell Therapy in Panama Motivates Tony Robbins, NY Times #1 Best-selling Author!

Image of Motivational Speaker Tony Robbins at Stem Cell Institute in Panama

“Feeling absolutely invigorated after our trip to Panama this weekend, where I received the transformative benefits of stem cell therapy! Our huge thanks and honor to all the doctors and the bright, caring medical staff at the state-of-the-art Stem Cell Institute in Panama City, Panama 🇵🇦. Stem cells saved my shoulder after struggling with excruciating pain from spinal stenosis and, more recently, a torn rotator cuff. Stem cell treatment is truly a next-level health innovation that can reverse the wear and tear we put on our bodies and prevent debilitating disease and injury from escalating further 🔬. This technological advancement will impact humanity in life-changing ways— it has the potential to transform and save MILLIONS of lives!…”  View Original Instagram Post
.

Read Dr. Riordan’s Amazon #1 best-selling book about stem cell therapy today

“Neil takes readers on a riveting journey through the past, present and future of stem cell therapy. His well-researched, educational and entertaining book could change your life. I highly recommend it.”Tony Robbins, NY Times #1 Bestselling Author 

Image of Stem Cell Therapy - A Rising Tide Book Cover

Stem cells are the repair cells of your body. When there aren’t enough of them, or they aren’t working properly, chronic diseases can manifest and persist.

Neil H Riordan, PA, PhD, author of MSC: Clinical Evidence Leading Medicine’s Next Frontier, the definitive textbook on clinical stem cell therapy, brings you an easy-to-read book about how and why stem cells work, and why they’re the wave of the future.

From industry leaders, sport stars, and Hollywood icons to thousands of everyday, ordinary people, stem cell therapy has helped when standard medicine failed. Many of them had lost hope. These are their stories.

Purchase

Treatment with Umbilical Cord Stem Cells Safe with Sustained Benefits for MS, Trial Shows

Image of GMP syringe prep lab at Stem Cell Institute clinic in Panama.

Stem cells being prepared for treatment.

March 20, 2018
Jose Marques Lopes, PhD
Link to Original Story at Multiple Sclerosis News Today

Treatment with umbilical cord [tissue-derived mesenchymal] stem cells was found to be safe and leads to sustained improvements in disability and brain lesions of multiple sclerosis (MS) patients, according to a clinical trial.

The study, “Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis,” was published in the Journal of Translational Medicine.

Although current treatments for MS are able to reduce the frequency of flare-ups and slow disease progression, they are not able to repair the damage to nerve cells or the myelin sheath, the protective layer around nerve fibers.

Mesenchymal stem cells (MSCs) are adult stem cells found in multiple tissues, such as umbilical cord, bone marrow, and fat. These cells are able to mature into bone, cartilage, muscle, and adipose tissue cells.

MSCs may inhibit immune-mediated alterations. In particular, MSCs derived from the umbilical cord have a high ability to grow and multiply, increase the production of growth factors, and possess superior therapeutic activity, compared with other MSCs.

Diverse clinical studies have shown that MSCs can safely treat certain immune and inflammatory conditions, including MS.

The research team had previously demonstrated that MSCs can also improve cognitive and motor function.

Recent results with placenta or umbilical cord MSCs showed few mild or moderate adverse events, as well improvements in patients’ level of disability.

Researchers at the Stem Cell Institute in Panama have now completed a one-year Phase 1/2 clinical study (NCT02034188) to test the effectiveness and safety of umbilical cord MSCs for the treatment of MS.

The trial included 20 MS patients with a mean age of 41 years, 60 percent of whom were women. Fifteen participants had relapsing-remitting MS, four had primary progressive MS, and one had secondary progressive MS. Patients’ disease duration was a mean of 7.7 years.

Participants received seven intravenous infusions of 20×106 umbilical cord MSCs over seven days. The treatment’s effectiveness was evaluated at the start, at one month, and at one year after treatment.

Assessments included evaluating brain lesions with magnetic resonance imaging (MRI) and disability based on the Kurtzke Expanded Disability Status Scale (EDSS), as well as validated MS tests for neurological function, hand function, mobility, and quality of life.

Patients did not report any serious adverse events. Most mild adverse events possibly related to treatment were headaches, which are common after MSC infusions, and fatigue, which is common in MS patients, the authors observed.

Improvements were most evident at one month after treatment, namely in the level of disability, nondominant hand function, and average walk time, as well as bladder, bowel, and sexual dysfunction. Patients also reported improved quality of life.

MRI scans at one year after treatment revealed inactive lesions in 15 of 18 evaluated patients. One patient showed almost complete elimination of lesions in the brain, which “is a particularly encouraging finding,” the researchers wrote.

At the one year point, improvements in disability levels were also still present, and could translate into improved ability to walk and work without assistance.

“The potential durable benefit of UCMSC [umbilical cord MSC] at 1 month, and sustained in some measures to 1 year, is in stark contrast to current MS drug therapies, which are required to be taken daily or weekly,” the researchers wrote.

The safety of the treatment is another advantage over available MS therapies, the team said.

They concluded that “treatment with UCMSC intravenous infusions for subjects with MS is safe, and potential therapeutic benefits should be further investigated.”

Podcast: Listen to Dr. Mike Hutchinson, DVM interview with Dr. Riordan about stem cell therapy

About This Episode

Delve deeper into the stem cell world with pioneer and expert Dr. Neil Riordan. Co-founder/chief science officer of the Riordan-McKenna Institute, founder/chairman/chief science officer of the Stem Cell Institute and author of Stem Cell Therapy: A Rising Tide, he’s here to discuss ongoing stem cell studies with Duchenne Muscular Dystrophy, spinal cord injuries, MS, autism and more. He’ll also answer one of the most common stem cell questions: how can one cell treat so many different conditions?

View on drmikehutchinson.com

New Study Suggests Healthy Donor Stem Cells Better Than MS Patient’s Own Stem Cells

Pre-Existing Inflammatory Diseases Reduce Therapeutic Potential of Stem Cells for MS Treatment, Study Shows

BY ALICE MELÃO (Original Story from Multiple Sclerosis News Today)

Pre-existing inflammatory diseases affecting the central nervous system make mesenchymal stem cells (MSCs) less effective in treating multiple sclerosis (MS), concludes a study by researchers at Cleveland’s Case Western Reserve University School of Medicine.

Diseases like EAE and MS diminish the therapeutic functionality of bone marrow MSCs, prompting re- evaluation about the ongoing use of autologous MSCs as a treatment for MS,” the team wrote, adding that its study supports the advancement of MSC therapy from donors rather than autologous MSC therapy to treat MS while raising “important concerns over the efficacy of using autologous bone marrow MSCs in clinical trials.

The study, “CNS disease diminishes the therapeutic functionality of bone marrow mesenchymal stem cells,” notes that MSCs potentially produce several signaling proteins that can regulate immune system responses as well as help tissue regenerate. Preclinical studies have shown that this can reduce brain inflammation while improving neural repair in animal models of experimental autoimmune encephalomyelitis (EAE). This model resembles the inflammation and neuronal damage seen in MS patients.

Given the need for effective new MS therapies, the results will help MSCs to advance to human clinical trials. So far, results have reported good safety data, though such therapies have failed to demonstrate therapeutic efficacy. Most such trials so far have used stem cells collected from the patient, a process known as autologous transplantation — yet this may explain why MSCs have not been effective. It’s possible that pre-existing neurological conditions may alter stem cells’ responsiveness as well as their therapeutic activity.

To see whether that is in fact the case, team members collected stem cells from the bone marrow of EAE mice. But these stem cells were unable to improve EAE symptoms, whereas stem cells collected from healthy mice retained all their therapeutic potential and improved EAE symptoms.

A more detailed analysis showed that the MSCs derived from EAE animals had different features than their healthy counterparts.

In addition, the team confirmed that MSCs collected from MS patients were also less effective in treating EAE animals, compared to MSCs from healthy controls. Indeed, these MSCs from patients produced pro-inflammatory signals instead of the protective anti-inflammatory ones.

“Diseases like EAE and MS diminish the therapeutic functionality of bone marrow MSCs, prompting re- evaluation about the ongoing use of autologous MSCs as a treatment for MS,” the team wrote, adding that its study supports the advancement of MSC therapy from donors rather than autologous MSC therapy to treat MS while raising “important concerns over the efficacy of using autologous bone marrow MSCs in clinical trials.”

Stem Cell Therapy for Heart Failure – Anita Ciszewski’s Story

The heart attack I had at 44 was a massive one – a 3 on a scale of 4, so the damage was very bad. When you get a 3, you know at 4 you’re dead. The whole left side was damaged, and it was the hospital’s fault because back then when a woman went in with chest pain they didn’t care 20 years ago. If I’d been a man they’d have paid more attention but because I was young, they left me for six hours and did nothing. During those six hours, I was in full-blown heart attack mode and imagine the damage that was done. The nurses kept saying it but nobody else noticed. The waiting list in Canada for the bypass was a year and a half and that’s how we ended up in Miami with Dr. Kretchmar. He is the doctor I trust. He’s been with me for 20 years. I felt good after my bypass for about ten years and then I started going downhill, started getting blockages again. I’ve got three stents implanted not to mention a torn artery. That’s when Dr. Kretchmar recommended that I go to Panama for stem cells.

So, I got on a plane with my son and went for the treatment at the Stem Cell Institute. I went back six months later, not because I had to, because I wanted to, I didn’t want to take any chances of any fall back. I wanted to be on the safe side. I went the second time and the side effects weren’t that bad, there were hardly any side effects.

I found the second treatment was even better than the first. I was getting more energy, I was doing things . . . I could kneel down and pick something up and get up again, but I noticed in the summertime working around the pool that I was able to pick up leaves, vacuum the pool, and doing things that I haven’t done in a couple of years.

I decided again on my own that I was going back again. I went again the third time and I’ve been going every six months. After the third one, I realized I didn’t need nitro anymore. I wasn’t using the nitro patch, nor was I using the nitroglycerin spray. I had no angina. I was shocked. I couldn’t believe it. Before, I couldn’t go up a flight of stairs without stopping halfway!

Thing were progressing so well that I said, can I come back again? I just wanted this to keep going that way. I did have a fourth treatment in October. After the fourth treatment, we decided that we’ll wait a year because four is quite a bit, and I’m feeling . . . as long as I feel like I’m doing great, there’s no point in me just going for the sake of going. It’s all good

I used to get up and fall asleep all over the place. I’d get up in the morning, grab a cup of coffee, and then I was sleeping with my coffee in my hands. I didn’t even know I was sleeping. I would take my granddaughter to see a movie and she’d be waking me up after the movie was over. I just could not stay awake. I felt so weak; zero energy, none whatsoever. I’ve seen a huge, huge difference. I’ve mentioned it to so many people that know me already. I say, “listen guys, I’ve gone there four times, had four treatments, and I’ll go back again if I have to.” For me that was my saving grace.

High-Dose Intravenous Vitamin C Therapy at Riordan Clinic Offers New Hope to Young Cancer Patient After Chemotherapy Fails

WICHITA, KANSAS (PRWEB) NOVEMBER 15, 2016

Hoyt Lee

Hoyt Lee

After undergoing failed chemotherapy treatments and the debilitating side effects that go along with them, things are finally looking up for 6 year-old cancer patient, Hoyt Lee. Since starting high-dose intravenous vitamin C therapy at the Riordan Clinic in Wichita, Kansas two and a half years ago, Hoyt’s condition stabilized and is now improving; something his oncologists said would likely never happen.

At just three months of age, doctors diagnosed Hoyt Lee with Neurofibromatosis 1 (NF-1). At 16 months old, he started chemotherapy for a brain tumor. After completing a grueling year of drug cocktails that wracked his young body, Hoyt’s mother, Shawna Overbey, received the news that she’d feared the most. Hoyt’s tumors were not responding to the chemo. They were growing.
Magnetic Resonance Imaging (MRI) showed accelerated tumor growth in his optic nerve chiasm. The optic chiasm is an X-shaped structure formed by the crossing of the optic nerves in the brain. The tumor was affecting his right and left eyes, his pituitary gland, and his hypothalamus.

The only available treatment alternatives were radiation or a different chemotherapy cocktail that can cause nerve damage and affect motor skills like walking and hand movement.

That’s when Shawna knew there had to be another way. Countless hours of research lead Shawna and Hoyt to Dr. Ron Hunninghake at the Riordan Clinic, a non-profit organization in Wichita, Kansas that specializes in alternative cancer therapies. The Riordan Clinic was founded in 1975 by Dr. Hugh Riordan and benefactor Olive W. Garvey. It has been providing IV therapy to patients like Hoyt for the past 40 years.

The late Dr. Riordan and his son, Neil H. Riordan, PhD, were pioneers in the use of vitamin C to treat cancer. Far ahead of their time, they invented patents (6,448,287, 6,436,411, 6,284,786) on treating cancer with vitamin C that date back prior to the turn of this century. For the past 20 years, Nina Mikirova, PhD has carried on their cancer research at the clinic.

At present, Neil Riordan, PhD is a renowned applied stem cell therapy researcher whose clinic in Panama, Stem Cell Institute, specializes in treating inflammatory and autoimmune related conditions with human *umbilical cord tissue–derived mesenchymal stem cells. Dr. Riordan has also teamed up with board-certified orthopedic surgeon, Wade McKenna, DO to bring stem cell therapy for orthopedic conditions to Southlake, Texas at the Riordan-McKenna Institute (RMI). RMI uses a proprietary mixture of the patient’s own bone marrow stem cells with *amniotic tissue products. Patients can receive intravenous high-dose vitamin C and other intravenous nutritional supplements at Riordan Wellness, which occupies space at the RMI building in Southlake.

Decades after the Riordans’ pioneering research, ascorbic acid treatment for cancer is entering the mainstream, with clinical trials being conducted at John’s Hopkins, University of Iowa, Jefferson University and Cornell. A clinical trial on vitamin C and prostate cancer was recently completed at Copenhagen University Hospital at Herlev, Denmark and in a study published November 5th in Science, a team of researchers from Weill Cornell Medicine, Cold Spring Harbor Laboratory, Tufts Medical Center, Harvard Medical School and The Johns Hopkins Kimmel Cancer Center found that high doses of vitamin C – roughly equivalent to the levels found in 300 oranges – impaired the growth of KRAS mutant and BRAF mutant colorectal tumors in cultured cells and mice.

Since undergoing IV high-dose vitamin C therapy, Hoyt Lee’s progress has been miraculous. According to his mother, MRIs have shown tumor stability or shrinkage over the past two and a half years. The tumor is no longer affecting his right eye, pituitary gland or hypothalamus. As of February 2016, there is almost no sign of a tumor in Hoyt’s optic nerve chiasm. Hoyt is doing so well that he won’t have to return to the hospital for another year.

“As Schopenhauer said, ‘All truth passes through three stages. First, it is ridiculed. Second, it is violently opposed. Third, it is accepted as being self-evident.’,” said Dr. Riordan. “As far as high-dose vitamin C goes, I think that, fortunately, we are finally entering the third stage,’ he added.

“We are delighted with Hoyt’s progress and equally proud that through generous charitable contributions, we’ve been able to do it without the crushing costs that can be associated with conventional treatments like chemotherapy,” commented Donna Kramme, CEO of Riordan Clinic. “It can cost as much as $15,000 per year to treat a child like Hoyt. We ask that everyone who is passionate about helping children like Hoyt please contact the Riordan Clinic to donate today. Without your help we cannot continue vital research that will make Hugh Riordan’s dream four decades ago, a reality today and into the future,” she concluded.

About Riordan Clinic

Riordan Clinic is a not-for-profit 501(c)(3), nutrition-based health facility in Wichita, Kansas. We have integrated lifestyle and nutrition to help you find the underlying causes of your illness. Since our inception in 1975, our mission has been clear and unwavering. Our functional medicine providers “stimulate an epidemic of health.”

People turn to the Riordan Clinic to restore, improve, and maintain health. Our integrative health practitioners listen to the needs of patients. Then we test and measure to map out a research-based, nutrition-fueled path to well being. Together, our professionals move beyond simply treating symptoms to address illness at its cause. Your Way to Well communicates a positive, hope-filled message. It stresses our individualized approach and achieves the best possible outcomes.

Riordan Clinic Website: http://www.riordanclinic.org

Riordan Clinic
3100 N. Hillside Ave.
Wichita, Kansas
67219

Tel: (316) 682-3100
Fax: (316) 682-2062

About Riordan-McKenna Institute (RMI)

RMI specializes in non-surgical treatment of acute and chronic orthopedic conditions using *amniotic tissue allograft and bone marrow aspirate concentrate (BMAC) that is harvested using the patented BioMAC bone marrow aspiration cannula. Common conditions treated include meniscal tears, ACL injuries, rotator cuff injuries, runner’s knee, tennis elbow, and joint pain due to degenerative conditions like osteoarthritis.

Additionally, RMI augments orthopedic surgeries with BMAC and amniotic tissue allograft to promote better post-surgical outcomes and uses amniotic membranes as part of a complete wound care treatment regimen.

BMAC contains a patient’s own mesenchymal stem cells (MSC,) hematopoietic stem cells (CD34+), growth factors and other progenitor cells. Amniotic tissue allograft is composed of collagens and other structural proteins, which provide a biologic matrix that supports angiogenesis, tissue growth and new collagen during tissue regeneration and repair.
*Amniotic tissue is donated after normal healthy births.

Riordan-McKenna Institute Website: http://www.rmiclinic.com

Riordan-McKenna Institute
801 E. Southlake Blvd.
Southlake, Texas
76092

Tel: (817) 776-8155
Toll Free: (877) 899-7836
Fax: (817) 776-8154

About Stem Cell Institute Panama

Founded in 2007 on the principles of providing unbiased, scientifically sound treatment options; the Stem Cell Institute (SCI) has matured into the world’s leading adult stem cell therapy and research center. In close collaboration with universities and physicians world-wide, our comprehensive stem cell treatment protocols employ well-targeted combinations of autologous bone marrow stem cells, autologous adipose stem cells, and donor human umbilical cord stem cells to treat: autism, cerebral palsy, multiple sclerosis, spinal cord injury, osteoarthritis, rheumatoid arthritis, heart disease, and autoimmune diseases.

In partnership with Translational Biosciences, a subsidiary of Medistem Panama, SCI provides clinical services for ongoing clinical trials that are assessing safety and signs of efficacy for autism, multiple sclerosis, osteoarthritis, rheumatoid arthritis, and spinal cord injury using allogeneic umbilical cord tissue-derived mesenchymal stem cells (hUC-MSC) and hU-MSC-derived mesenchymal trophic factors (MTF). In 2017, Translation Biosciences plans to expand its clinical trial portfolio to include heart disease and cerebral palsy.

For more information on stem cell therapy:

Stem Cell Institute Website: https://www.cellmedicine.com

Aquilino de la Guardia Street
BICSA Financial Center
63rd Floor
Panama City, Panama

*Tissue is donated after normal, healthy births.

Applied Stem Cell Therapy Expert, Neil Riordan, PhD, Authors “Cell Therapy for Liver Failure: A New Horizon” in Contemporary Liver Transplantation Medical Reference

DALLAS-FORT WORTH, TEXAS (PRWEB) NOVEMBER 08, 2016 (Original Press Release on PRWeb)

Picture of Neil Riordan, PhD

Neil Riordan, PhD

A new chapter by renowned applied stem cell therapy expert, Neil Riordan, PhD of the Riordan-McKenna Institute in Southlake, Texas; Medistem Labs Panama, and the Stem Cell Institute in Panama City, Panama, entitled, “Cell Therapy for Liver Failure: A New Horizon” is now available in the printed and online medical reference, “Contemporary Liver Transplantation – The Successful Liver Transplant Program”.

Contemporary Liver Transplantation provides a comprehensive review of the most crucial and provocative aspects of liver transplantation. The reference covers all disciplines involved in a multidisciplinary liver transplant team; provides a valuable resource for surgeons, hepatologists, anesthesiologists, transplant coordinators and administrators, amongst others; addresses organizational issues that are vital to the good performance of transplant programs; and offers the first 360-degree analysis of liver transplantation.

Liver failure is the seventh largest cause of death in industrialized countries. It occurs as a result of a number of acute and chronic clinical inciting factors, including drug-/alcohol-induced hepatotoxicity, viral infections, vascular injury, autoimmune disease, or genetic predisposition. The only available cure, liver transplantation, is severely limited by a lack of donors and further complicated by the adverse effects of chronic immune suppression.

In his chapter on stem cell therapy for liver failure, Dr. Riordan examines pre-clinical data and analyzes published clinical trials to identify promising sources of autologous stem cells to treat liver failure including: bone marrow mesenchymal stem cells (BM-MSC), adipose tissue MSC (AT-MSC), and bone marrow mononuclear cells (BMMC) including their purified forms. In addition, he delves into allogeneic stem cells such as those harvested from umbilical cords after normal, healthy births.

“Many liver failure patients contact our clinics in Panama and Texas asking if there is anything we can do for them. Unfortunately, we have to tell them that we cannot treat liver failure. Even though some clinical trials have shown signals of efficacy, which is encouraging, I don’t think sufficient rationale exists to treat liver failure patients with the types of stem cells I’ve studied at present,” stated Dr. Riordan.

About Riordan-McKenna Institute (RMI)

RMI specializes in non-surgical treatment of acute and chronic orthopedic conditions using *amniotic tissue allograft and bone marrow aspirate concentrate (BMAC) that is harvested using the patented BioMAC bone marrow aspiration cannula. Common conditions treated include meniscal tears, ACL injuries, rotator cuff injuries, runner’s knee, tennis elbow, and joint pain due to degenerative conditions like osteoarthritis.

Additionally, RMI augments orthopedic surgeries with BMAC and amniotic tissue allograft to promote better post-surgical outcomes and uses amniotic membranes as part of a complete wound care treatment regimen.

BMAC contains a patient’s own mesenchymal stem cells (MSC,) hematopoietic stem cells (CD34+), growth factors and other progenitor cells. Amniotic tissue allograft is composed of collagens and other structural proteins, which provide a biologic matrix that supports angiogenesis, tissue growth and new collagen during tissue regeneration and repair.

*Amniotic tissue is donated after normal healthy births.

Riordan-McKenna Institute Website: http://www.rmiclinic.com

Riordan-McKenna Institute
801 E. Southlake Blvd.
Southlake, Texas 76092

Tel: (817) 776-8155
Toll Free: (877) 899-7836
Fax: (817) 776-8154

About Stem Cell Institute Panama

Founded in 2007 on the principles of providing unbiased, scientifically sound treatment options; the Stem Cell Institute (SCI) has matured into the world’s leading adult stem cell therapy and research center. In close collaboration with universities and physicians world-wide, our comprehensive stem cell treatment protocols employ well-targeted combinations of autologous bone marrow stem cells, autologous adipose stem cells, and donor *human umbilical cord stem cells to treat: autism, cerebral palsy, multiple sclerosis, spinal cord injury, osteoarthritis, rheumatoid arthritis, heart disease, and autoimmune diseases.

In partnership with Translational Biosciences, a subsidiary of Medistem Panama, SCI provides clinical services for ongoing clinical trials that are assessing safety and signs of efficacy for autism, multiple sclerosis, osteoarthritis, rheumatoid arthritis, and spinal cord injury using allogeneic umbilical cord tissue-derived mesenchymal stem cells (hUC-MSC) and hU-MSC-derived mesenchymal trophic factors (MTF). In 2017, Translation Biosciences plans to expand its clinical trial portfolio to include heart disease and cerebral palsy.
*umbilical cord tissue is donated after normal, healthy births

For more information on stem cell therapy:

Stem Cell Institute Website: http://www.cellmedicine.com
Stem Cell Institute
Via Israel & Calle 66
Plaza Pacific Office #2A
Panama City, Panama

About Medistem Panama Inc.
Since opening its doors in 2007, Medistem Panama Inc. has developed adult stem cell-based products from human umbilical cord tissue and blood, adipose (fat) tissue and bone marrow. Medistem operates an 8000 sq. ft. ISO 9001-certified laboratory in the prestigious City of Knowledge. The laboratory is fully licensed by the Panamanian Ministry of Health and features 3 class 10000 clean rooms, class 100 laminar flow hoods, and class 100 incubators.

Medistem Panama Website: http://www.medistempanama.com

About Contemporary Liver Transplantation

Edited by Cataldo Doria, Contemporary Liver Transplantation provides a comprehensive review of the most crucial and provocative aspects of liver transplantation. It represents a unique source of information and guidance for the current generation of transplant surgeons that evolved from being pure clinicians into savvy administrators knowledgeable in every regulatory aspect governing transplantation.

The book contains 35 chapters covering every single aspect of the surgical operation in the donors as well as the recipients of liver transplants. The pre-operative work-up, as well as the post-operative immunosuppression management and the treatment of recurrent diseases are addressed in detail. Single chapters are dedicated to controversial issues like transplantation in patients diagnosed with NASH, transplantation for patients diagnosed with HCC beyond Milan criteria and usage of HIV positive donors. Dedicated chapters on HCV, HCC, FHF and NASH will make this book a unique resource for any health care provider part of the multidisciplinary liver transplant team.

The book goes beyond the analysis of the formal medical and surgical aspects of liver transplantation and introduces deep knowledge on key aspects of contemporary transplant programs, such as: physical rehabilitation, palliative care, pregnancy, the multiple requirements of regulatory agencies ruling transplantation, quality measurements for transplant programs, finance and liability.

The book is organized in 9 sections focusing on each key aspect of liver transplantation. Contemporary Liver Transplantation addresses the need and the questions of the multidisciplinary group involved including surgeons, Hepatologists, anesthesiologists, infectious disease specialists, radiologists, transplant coordinators, financial specialists, epidemiologists and administrators.

Contemporary Liver Transplantation Online: http://www.springer.com/us/book/9783319072081

FDA poised to outlaw breast reconstruction for breast cancer survivors using their own fat tissue

FDA-NotApprovedStampThe U.S. Food and Drug Administration held public hearings for two days this week to allow for public commenting on proposed guidance relating to the regulation of human cells, tissues or tissue-based products.

In its current form, this guidance will classify a woman’s own fat tissue as a drug when used in breast reconstruction procedures. This is certainly bad news for the over 100,000 female cancer patients who seek this procedure each year.

According to the FDA, the sole purpose of a woman’s breast is to lactate. Of course that begs the question of what the purpose of a man’s breast might be but we will leave that for another day. Since fat from other parts of the body does not produce milk, it cannot be transferred into a woman’s breast.

Specifically, in its industry guidance entitled Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) from Adipose Tissue: Regulatory Considerations; Draft Guidance, the FDA states, “The basic function of breast tissue is to produce milk (lactation) after childbirth. Because this is not a basic function of adipose [fat] tissue, using HCT/Ps from adipose tissues for breast augmentation would generally be considered a non-homologous use.” “Homologous use” refers to a tissue’s ability to serve the same “basic function or functions” as the tissue into which it is being transplanted. So in this case, “non-homologous” use equals FDA-regulated “drug”.

That’s right ladies. Your fat tissue is an FDA-regulated drug if your doctor wishes to use it to help reconstruct your breasts following a mastectomy unless she goes through the FDA drug approval process, which can take a decade or two and cost upwards of 2 billion dollars. Needles to say, this is a financial burden that no doctor, clinic or hospital can bear. Once finalized, this new guidance will effectively shut the door on using a woman’s own fat tissue to help reconstruct her breasts.

And it doesn’t stop there. According to the FDA, in most cases, our own cells are drugs too. An FDA panel member even went so far as to state that our blood is an FDA-regulated drug.

For example, if your doctor wants to remove a small sample of bone marrow from your hip and inject part of it into your knee because she has read the literature and believes it can help you heal without surgery, the FDA says that’s verboten because you guessed it – it’s a drug that is subject to the full FDA drug approval process.

As the FDA becomes increasing intrusive in our lives, restricting the ability of licensed medical doctors to practice medicine, one has to wonder where it all will end? The answer seems to be that once the FDA has its way, our bodies, down to the very last cell, will be classified as drugs, and therefore subject to federal regulation by the FDA.

If you agree that the FDA has no business outlawing the use of your own fat tissue to reconstruct your breasts, please spread the word and ask your friends, family members and doctors to let the FDA know what you think before September 27th by commenting here: https://www.regulations.gov/comment?D=FDA-2014-D-1856-0061

You might also consider contacting your local congressman, congresswoman, and state senators.

2016-09-15T16:40:41+00:00 September 15th, 2016|Bone Marrow Stem Cells, Breast Cancer, Cancer, FDA, News|